CN108473516B - 3,5-二苯基-二唑化合物的水溶性衍生物 - Google Patents

3,5-二苯基-二唑化合物的水溶性衍生物 Download PDF

Info

Publication number
CN108473516B
CN108473516B CN201680073089.1A CN201680073089A CN108473516B CN 108473516 B CN108473516 B CN 108473516B CN 201680073089 A CN201680073089 A CN 201680073089A CN 108473516 B CN108473516 B CN 108473516B
Authority
CN
China
Prior art keywords
disease
compound
protein
amyloidosis
hereditary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073089.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473516A (zh
Inventor
阿米尼·吉斯
菲利克斯·施密特
克里斯蒂安·格里辛格
安德烈·列昂诺夫
谢尔盖·梁赞诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of CN108473516A publication Critical patent/CN108473516A/zh
Application granted granted Critical
Publication of CN108473516B publication Critical patent/CN108473516B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680073089.1A 2015-12-14 2016-12-14 3,5-二苯基-二唑化合物的水溶性衍生物 Active CN108473516B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15199972 2015-12-14
EP15199972.9 2015-12-14
PCT/EP2016/081084 WO2017102893A1 (en) 2015-12-14 2016-12-14 Water-soluble derivatives of 3,5-diphenyl-diazole compounds

Publications (2)

Publication Number Publication Date
CN108473516A CN108473516A (zh) 2018-08-31
CN108473516B true CN108473516B (zh) 2021-06-18

Family

ID=54850017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073089.1A Active CN108473516B (zh) 2015-12-14 2016-12-14 3,5-二苯基-二唑化合物的水溶性衍生物

Country Status (21)

Country Link
US (1) US10308671B2 (enExample)
EP (1) EP3390412B1 (enExample)
JP (1) JP6898931B2 (enExample)
KR (1) KR102671166B1 (enExample)
CN (1) CN108473516B (enExample)
AU (1) AU2016372408B2 (enExample)
BR (1) BR112018011994B1 (enExample)
CA (1) CA3008334C (enExample)
CL (1) CL2018001570A1 (enExample)
DK (1) DK3390412T3 (enExample)
ES (1) ES2873510T3 (enExample)
HU (1) HUE054815T2 (enExample)
IL (1) IL260011B (enExample)
MX (1) MX379522B (enExample)
NZ (1) NZ742979A (enExample)
PH (1) PH12018501276A1 (enExample)
PL (1) PL3390412T3 (enExample)
PT (1) PT3390412T (enExample)
RU (1) RU2764131C2 (enExample)
WO (1) WO2017102893A1 (enExample)
ZA (1) ZA201803865B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH713150A2 (fr) * 2016-11-23 2018-05-31 Eta Sa Mft Horlogere Suisse Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre.
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US20250161273A1 (en) * 2022-03-01 2025-05-22 Modag Gmbh Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
CN116399983B (zh) * 2023-06-09 2023-08-15 天津辰欣药物研究有限公司 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056903A (zh) * 2008-06-09 2011-05-11 路德维希马克西米利安慕尼黑大学 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药
CN104350042A (zh) * 2012-06-08 2015-02-11 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
EP2272822A4 (en) * 2008-03-31 2012-01-18 Renascience Co Ltd PLASMINOG ACTIVATOR-1 HEMMER
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056903A (zh) * 2008-06-09 2011-05-11 路德维希马克西米利安慕尼黑大学 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药
CN104350042A (zh) * 2012-06-08 2015-02-11 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Prodrugs: design and clinical applications;Jarkko Rautio等;《nature reviews》;20080125;第7卷;第255-270页 *

Also Published As

Publication number Publication date
RU2018125590A (ru) 2020-01-20
CA3008334C (en) 2024-01-02
ZA201803865B (en) 2019-04-24
DK3390412T3 (da) 2021-06-21
RU2764131C2 (ru) 2022-01-13
KR20180089511A (ko) 2018-08-08
PL3390412T3 (pl) 2021-10-25
CA3008334A1 (en) 2017-06-22
PH12018501276A1 (en) 2019-01-28
ES2873510T3 (es) 2021-11-03
IL260011B (en) 2021-12-01
PT3390412T (pt) 2021-06-22
US20180370997A1 (en) 2018-12-27
MX2018006877A (es) 2018-09-18
IL260011A (en) 2018-07-31
CL2018001570A1 (es) 2018-12-28
JP2019501167A (ja) 2019-01-17
EP3390412B1 (en) 2021-04-14
MX379522B (es) 2025-03-10
WO2017102893A1 (en) 2017-06-22
KR102671166B1 (ko) 2024-05-31
CN108473516A (zh) 2018-08-31
RU2018125590A3 (enExample) 2020-04-21
AU2016372408A1 (en) 2018-06-21
NZ742979A (en) 2022-05-27
US10308671B2 (en) 2019-06-04
JP6898931B2 (ja) 2021-07-07
BR112018011994A2 (pt) 2018-12-04
BR112018011994B1 (pt) 2022-07-19
EP3390412A1 (en) 2018-10-24
HUE054815T2 (hu) 2021-10-28
AU2016372408B2 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
CN108473516B (zh) 3,5-二苯基-二唑化合物的水溶性衍生物
WO2018096504A1 (en) Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs
JP2020508985A (ja) 治療用デンドリマー
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
CZ295618B6 (cs) Pyrazinové deriváty, způsob výroby a farmaceutický prostředek
AU2004309395A1 (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
JP2012176963A (ja) 改善された薬剤候補およびその調製法
CN111372579B (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
KR20050119104A (ko) 치환된 퀴놀린과 치환된 디페닐설폰을 함유하는 조성물과방법
JP6445046B2 (ja) １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ
US10464883B2 (en) Compounds and methods for the treatment of neurodegenerative diseases
CN121889397A (zh) 化合物或其盐及其制造方法、包含化合物或其盐的药物组合物及其制造方法
US20210205348A1 (en) Methods for the Treatment of Bladder Cancer
TW202340195A (zh) 作為嗜中性白血球彈性蛋白酶抑制劑之三唑酮衍生物鹽
US20190270698A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
JP7053762B2 (ja) Ｓａｐ枯渇剤としてのｄ－プロリン誘導体
JPH07507314A (ja) カルシウム及びホスフェート代謝異常治療用ホスホノスルホネート化合物
JPH11130792A (ja) 虚血性疾患予防、治療剤及び臓器保存剤
JP7828354B2 (ja) 中枢神経系への低疎水性の生物活性薬に対して化学的にカップリングされたトランスポーター
JP2006520768A (ja) 金属イオンのキレート化剤として有用な窒素含有多環式誘導体およびそれらの用途
EA051030B1 (ru) Соль производного триазолона в качестве ингибитора нейтрофилэластазы
JP2007246533A (ja) 抗炎症性ホスホネート化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240624

Address after: Munich, Germany

Patentee after: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.

Country or region after: Germany

Address before: Munich, Germany

Patentee before: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.

Country or region before: Germany

Patentee before: Giese Armin

Patentee before: Felix Schmidt

TR01 Transfer of patent right